Champions Oncology Q1 FY2026 revenue $14.0M; adjusted EBITDA $60K vs $2.0M; CEO Rob Brainin appointed

CHAMPIONS ONCOLOGY, INC.

2026-Q1 EPS reported -$0.03 revenue$13,995,000

Revenue $14.0M, down from $14.1M YoY; operating loss of $527K vs income of $1.3M.
Adjusted EBITDA fell to $60K from $2.0M; gross margin 43% vs 50%.
Rob Brainin appointed CEO; previously CEO? He signs report as CEO as of Sept 15, 2025.
Cash on hand $10.3M with no debt; net cash from operations $600K.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.